To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide association study meta-analysis of 5,539 autoantibody-positive individuals with rheumatoid arthritis (cases) and 20,169 controls of European descent, followed by replication in an independent set of 6,768 rheumatoid arthritis cases and 8,806 controls. Of 34 SNPs selected for replication, 7 new rheumatoid arthritis risk alleles were identified at genome-wide significance (P < 5 × 10 −8 ) in an analysis of all 41,282 samples. The associated SNPs are near genes of known immune function, including IL6ST, SPRED2, RBPJ, CCR6, IRF5 and PXK. We also refined associations at two established rheumatoid arthritis risk loci (IL2RA and CCL21) and confirmed the association at AFF3. These new associations bring the total number of confirmed rheumatoid arthritis risk loci to 31 among individuals of European ancestry. An additional 11 SNPs replicated at P < 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles.
citrullinated peptide (anti-CCP) autoantibodies 2 . Genetic studies in autoantibody-positive rheumatoid arthritis among subjects of European ancestry have identified multiple risk alleles in the major histocompatibility complex (MHC) region, as well as 25 confirmed rheumatoid arthritis risk alleles in 23 non-MHC loci [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . These alleles explain about 23% of the genetic burden of rheumatoid arthritis 11 , indicating that additional alleles remain to be discovered.
To identify new rheumatoid arthritis risk alleles, we conducted a GWAS meta-analysis of 5,539 autoantibody-positive rheumatoid arthritis cases and 20,169 controls of European ancestry ( Table 1) . This study expands upon our previous GWAS meta-analysis of 3,393 cases and 12,462 controls 11 by (i) adding a new GWAS dataset of 483 rheumatoid arthritis cases recruited from the Boston area (Brigham Rheumatoid Arthritis Sequential Study, BRASS) and 1,449 shared controls, (ii) adding 513 cases and 431 controls recruited from Sweden (Epidemiological Investigation of Rheumatoid Arthritis, EIRA), (iii) incorporating a recently published GWAS of 2,418 cases and 4,504 controls recruited from North America (Canada and North American Rheumatoid Arthritis Consortium-III, NARAC-III) 13 , and (iv) adding additional shared controls to the NARAC-III dataset. For each of six GWAS case-control collections, we removed SNPs and individuals that failed quality control, matched case-control samples using principal-components analysis to minimize bias due to stratification, and imputed 16 genome-wide to infer genotypes at additional European (CEU) HapMap SNPs. We used logistic regression to conduct a GWAS for 2.56 million SNPs in each collection, corrected for residual inflation using genomic control 17 , and combined the results across collections by inverse variance-weighted meta-analysis to calculate P GWAS 18 . We found little evidence of systematic bias as indicated by the genomic control inflation factor (λ GC = 1.04) 17 , the quantile-quantile plots, the results for markers highly differentiated across Europe 19 or comparisons with an alternative analysis using principal-components analysis eigenvectors as covariates (Supplementary Figs. 1-4 and Supplementary Table 1; see Online Methods and Supplementary Note for full details of the analysis).
Our GWAS meta-analysis found support for rheumatoid arthritis risk loci previously confirmed among individuals of European ancestry, consistent with power for our study design ( Table 2 and Supplementary Fig. 5 ). Four of the 25 confirmed non-MHC risk alleles obtained P GWAS < 5 × 10 −8 (at the PTPN22, CTLA4, TNFAIP3 and CD40 loci); the remaining 21 confirmed alleles obtained P GWAS ≤ 0.002. We found modest evidence for association at PADI4 (rs2240340, P GWAS = 0.01, odds ratio (OR) = 1.06) and FCRL3 (rs3761959, P GWAS = 0.001, OR = 1.08), but not at CD244 (rs3753389, P GWAS = 0.26, OR = 1.03); SNPs at these three gene loci have been previously implicated in rheumatoid arthritis cases of Asian ancestry 3, 20, 21 (Supplementary Table 1) .
We used three criteria to select 34 independent SNPs for replication after removing previously confirmed rheumatoid arthritis risk alleles. First, we selected all 11 SNPs with P GWAS < 10 −6 . Second, we selected nine SNPs (of the total 116 SNPs tested) with P GWAS < 0.0001 and having been identified as functionally related to known rheumatoid arthritis l e t t e r S l e t t e r S risk loci by GRAIL 22 , a bioinformatic analysis tool that identifies connections among genes in published abstracts (Supplementary Fig. 6 ). Third, we selected 14 SNPs (of the total 104 SNPs tested) with P GWAS < 0.01 and previously known to be associated with other autoimmune diseases [23] [24] [25] [26] [27] [28] [29] [30] [31] , as we found evidence for enrichment of autoimmuneassociated SNPs in our rheumatoid arthritis GWAS ( Supplementary  Fig. 7 ). See Supplementary Note for additional details about our selection of SNPs for replication. These 34 SNPs were genotyped in an independent set of 6,768 autoantibody-positive rheumatoid arthritis cases and 8,806 matched controls of European ancestry ( Table 1) . As in our GWAS, all cases were seropositive for disease-specific autoantibodies (anti-CCP or rheumatoid factor). For each SNP, we tested for replication of the GWAS meta-analysis association by calculating a one-tailed P value (P replication ) for the same allele in both analyses. Additionally, we conducted overall association tests across all 41,282 samples (GWAS meta-analysis plus the replication samples, P overall ) and considered P overall < 5 × 10 −8 to be a reproducible level of significance for rheumatoid arthritis risk association.
Of the 34 SNPs tested, 12 obtained a Bonferroni-corrected P replication < 0.0015 (calculated as 0.05/34 total tests), and an additional nine SNPs obtained P replication < 0.05. Ten out of these 34 SNPs achieved genome-wide significance in the combined analysis (P overall < 5 × 10 −8 ), indicating that these are validated rheumatoid arthritis risk alleles ( Table 3) . The other 11 SNPs that achieved replication significance had P replication < 0.05 but had P overall > 5 × 10 −8 , indicating highly suggestive but not genome-wide significant association ( Table 4) . Results for all 34 SNPs in the replication and combined analyses are shown in Supplementary Table 2 .
Three of the ten newly validated rheumatoid arthritis risk loci have not been implicated in any previous genetic studies of rheumatoid arthritis or in studies of other autoimmune diseases. These SNPs are located at chromosome 2p14 (rs934734, P overall = 5.3 × 10 −10 ), 5q11 (rs6859219, P overall = 9.6 × 10 −12 ) and 5q21 (rs26232, P overall = 4.1 × 10 −8 ). Replication sample ORs for the minor alleles of these SNPs were 1.13, 0.85 and 0.93, respectively ( Table 3) .
Although no single gene can be declared causal as a result of this analysis, we labeled the new rheumatoid arthritis risk loci with the names of the most compelling candidate gene(s) from each region of linkage disequilibrium (LD) based upon GRAIL analysis and/or knowledge of rheumatoid arthritis pathogenesis 2, 22 . At 2p14, the most significant SNP (rs934734) is located within intron 1 of SPRED2, encoding the sprouty-related, EVH1 domain-containing protein 2 (Fig. 1a) , which has been shown to regulate CD45 + hematopoietic cells via the Ras-MAP kinase pathway 32 . At 5q11, the most significant SNP (rs6859219) is located in ANKRD55, an ankyrin repeat domain-containing gene of unknown function (Fig. 1b) . A more compelling immunological candidate, IL6ST, encoding interleukin 6 signal transducer, lies ~150 kb proximal to rs6859219 but outside the region of LD with associated SNPs. The IL6ST protein product, gp130, functions as a part of the receptor complex for the inflammatory cytokine IL6 (ref. 33) . At 5q21, there is no obvious biological candidate gene; rs26232 lies within the intron of the predicted gene C5orf30 (Fig. 1c) .
Our study provides the first convincing evidence that four loci implicated in other autoimmune diseases are also associated with risk of rheumatoid arthritis. Of these, three of the four SNPs were selected for replication based on obtaining P GWAS < 10 −6 , regardless of their previously reported associations with autoimmune disease. These three SNPs are located at chromosome 3p14 (rs13315591, near PXK, P overall = 4.6 × 10 −8 ), 4p15 (rs874040, near RBPJ, P overall = 1.0 × 10 −16 ) and 6q27 (rs3093023, in CCR6, P overall = 1.5 × 10 −11 ). The 3p14 SNP lies 187 kb proximal to a SNP associated with systemic lupus erythematosus (SLE) 25 ; the SLE SNP, intronic in the PXK gene, is only weakly associated with rheumatoid arthritis risk in our study (rs6445975, P GWAS = 0.03, r 2 = 0.15 and D′ = 0.75 with rs13315591). The 4p15 RBPJ SNP is in complete LD (r 2 = 1) with a SNP associated with risk of type 1 diabetes (T1D-associated SNP, rs10517086) 23 , and 22 , frequency in controls subjects), odds ratio (95% CI) and association P value are derived from our GWAS meta-analysis. Most SNPs have achieved P < 5 × 10 −8 in combined analysis from previous studies; those with an asterisk (*) have been validated by replication in independent samples but may not have attained P < 5 × 10 −8 in any single study. SNPs with strong evidence of association in Asians (including PADI4, rs2240340, P GWAS = 0.01; FCRL3, rs3761959, P GWAS = 0.001; and CD244, rs3753389, P GWAS = 0.26) or suggestive evidence of association in Europeans are shown in Supplementary table 1. Power was calculated based on the odds ratios from our meta-analysis at α = 10 −6 (a threshold for selecting SNPs for replication in the current study) and α < 5 × 10 −8 (the threshold for genome-wide significance). Details of the power calculations can be found in the Supplementary Note. l e t t e r S the same allele confers risk in both diseases. The 6q27 CCR6 SNP rs3093023 is in LD with a SNP associated with Crohn's disease 24 , which is only weakly associated with rheumatoid arthritis risk in our study (Crohn's-associated SNP rs2301436, P GWAS = 0.045, r 2 = 0.48 and D′ = 0.80).
The IRF5 SNP rs10488631 (P GWAS = 2.8 × 10 −6 ), chosen because of its association with SLE 34, 35 , was convincingly associated with autoantibody-positive rheumatoid arthritis in our study (P replication = 1.2 × 10 −6 , P overall = 4.2 × 10 −11 ). A previous study 36 proposed that the complex SLE risk associations in IRF5 are explained by three independent groups of SNPs, each consisting of SNPs in tight LD with each other. In our dataset, these groups are represented by rs10488631 (group 1), rs729302 (group 2) and rs4728142 (group 3). In addition to finding association with the group 1 SNP rs10488631, we found evidence for association with group 3 SNP rs4728142 (P GWAS = 7.2 × 10 −6 ), which is in LD with a variant that alters IRF5 polyadenylation and expression 36 . However, we found no evidence for association of the representative group 2 SNP (rs729302, P GWAS = 0.15). Conditional analyses indicated that the group 1 and group 3 effects are independent of each other (Supplementary Table 3) . We note that the group 3 SNP rs3807306 has been suggested to be associated with autoantibody-negative rheumatoid arthritis 37 ; however, GWAS, replication and combined meta-analysis results for SNPs with highly suggestive associations with rheumatoid arthritis risk (defined as P < 0.05 in our replication samples). As in table 2, listed for each SNP are the rs ID, chromosomal location (Chr.) and position, candidate gene(s), major and minor alleles, GWAS and replication analysis P value, OR and case and control minor allele frequencies, and the combined analysis P values for association and for the Cochran's Q test for heterogeneity.
a Selected for replication based on GRAIL-based P text score. b Selected for replication based on P GWAS < 0.01 and a validated autoimmune disease association: rs13119723, IL2-IL21 for rheumatoid arthritis and celiac disease; rs11594656, IL2RA for T1D and MS; rs2793108, ZEB1, T1D; rs3184504, SH2B3, celiac disease and T1D; rs2872507, IKZF3, Crohn's disease; rs11203203, UBASH3A for T1D; rs5754217, UBE2L3 for SLE; the ZEB1 SNP was from the May 2009 release of the online T1D database (see URLs). c Autoimmune disease associations for SNPs other than those tested for replication in the present study (see main text, Fig. 2 and the Supplementary Note): CD247 for Crohn's disease; IL2-IL21 for celiac disease, rheumatoid arthritis and T1D; IL2RA for MS, rheumatoid arthritis and T1D; BATF for T1D; CD19-NFATC2IP for T1D; IKZF3 for T1D; and UBASH3A for Crohn's disease and T1D.
l e t t e r S our results suggest that this SNP is associated with autoantibodypositive rheumatoid arthritis (P GWAS = 4.5 × 10 −6 ). Our GWAS meta-analysis identified new alleles exhibiting independent effects from previously implicated rheumatoid arthritis risk alleles at two other loci, CCL21 (rs951005, P overall = 3.9 × 10 −10 ) 11 and IL2RA (rs706778, P overall = 3.3 × 10 −11 ) 15 . Our new CCL21 SNP has little LD with the previous rheumatoid arthritis risk-associated SNP rs2812378 (P GWAS = 1.6 × 10 −7 , r 2 = 0.06 and D′ = 0.83) 11 . Conditional analyses indicated that the associations of these two SNPs are partly independent (Supplementary Table 3) ; the new SNP rs951005 remains significant (P = 1.7 × 10 −5 ) conditional on the previously known SNP rs2812378 and conditional on rs951005, the previously known rs2812378 remains nominally significant (P = 0.01).
SNPs at IL2RA are known to be associated with multiple autoimmune diseases, including rheumatoid arthritis 15 , T1D 23 and multiple sclerosis (MS) 38, 39 . The IL2RA SNP identified in our GWAS (rs706778, P overall = 3.3 × 10 −11 ; Fig. 1d ) is in partial LD with a SNP previously implicated in rheumatoid arthritis, T1D and MS (rs2104286, r 2 = 0.25 and D′ = 1) 15 , as well as a SNP previously implicated in T1D and MS (rs11594656, r 2 = 0.24 and D′ = 1) 23 Tables 3 and 4) . Previously validated autoimmune SNPs tested in our replication study. Eighteen SNPs tested in our replication samples were in LD (defined as r 2 > 0.3) with a validated autoimmune risk allele. Of these, five were validated as rheumatoid arthritis risk alleles in our study (P overall < 5 × 10 −8 , inner most circle), six were suggestive associations (P replication < 0.05 but P overall > 5 × 10 −8 ) and six demonstrated no evidence of association in our replication samples (P replication ≥ 0.05). For the 12 SNPs with suggestive or no evidence of association, each SNP is plotted by the strength of association with rheumatoid arthritis risk in the replication samples; those closer to the inner circle have more significant P replication . All of the rheumatoid arthritis risk alleles confer risk in the same direction as the validated autoimmune risk alleles (when the same allele or a near perfect proxy was tested). We include the following as 'autoimmune' diseases in our study, listed on the outside of the circle, although these reflect diseases along the autoimmune-inflammatory spectrum: systemic lupus erythematosus (SLE), celiac disease, Crohn's disease, multiple sclerosis (MS), psoriasis, and type 1 diabetes (T1D) but other autoimmune diseases are not included (for example, autoimmune thyroiditis). Note that there are SNPs associated with rheumatoid arthritis and other autoimmune diseases not shown; we only include those SNPs tested as part of the current study. See Online Methods for details about the SNPs validated in other autoimmune diseases. l e t t e r S A SNP at the AFF3 locus has been previously implicated in rheumatoid arthritis 14 , with equivocal evidence for association with T1D 23, 40 . Our study provides strong evidence that this locus is associated with risk of autoantibody-positive rheumatoid arthritis (rs11676922, P overall = 1.0 × 10 −14 , OR = 1.14).
Eighteen of the 34 SNPs that we tested in replication (based on the criteria above) are in LD with previously validated autoimmune risk alleles (Fig. 2) . Of these, five SNPs demonstrated genome-wide significance (P overall < 5 × 10 −8 ) and seven showed suggestive evidence of association (P replication < 0.05) in our study; only six SNPs showed no evidence of association in the replication stage. Though not meant as a complete comparison of all known rheumatoid arthritis and other autoimmune disease risk alleles, these results underscore the emerging overlap in the genetic bases of rheumatoid arthritis and other autoimmune diseases 41, 42 . Although additional replication in large sample collections is required to confirm the suggestive associations, many of the SNPs found here likely represent true rheumatoid arthritis risk alleles.
Several of the SNP associations seen here further implicate T cells in rheumatoid arthritis pathogenesis. RBPJ (encoding recombination site binding protein J and also known as CSL) encodes a transcription factor within the Notch signaling pathway. Rbpj-deficient mice have no T-cell development, whereas early B-cell development is maintained 43 . CCR6 is a cell surface protein that distinguishes Th17 cells from other CD4 + helper T cells 44 . Synoviocytes from arthritic joints of mice and individuals with rheumatoid arthritis produce CCL20, a CCR6 ligand. Notably, anti-Ccr6 monoclonal antibodies substantially inhibit mouse arthritis, suggesting that CCR6 could be a therapeutic target in human rheumatoid arthritis 44 . CD247 (P replication = 0.006, P overall = 1.6 × 10 −6 ; Table 3 ) encodes the T-cell receptor zeta chain, a subunit of the T-cell receptor-CD3 complex that, when altered, causes an inflammatory arthritis in mouse 45, 46 . The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. These results build upon knowledge of T-cell activation-differentiation in rheumatoid arthritis pathogenesis as evidenced by genetic associations at HLA-DRB1 (encoding a protein that presents antigens to T cells), PTPN22 (encoding a protein that alters T-cell thresholds), CTLA4 (encoding a co-stimulator for T-cell activation), IL2RA (encoding a protein that mediates IL2-dependent T-cell responses) and STAT4 (encoding a transcription factor involved in Th1 cell differentiation), among others.
In conclusion, we find convincing evidence for association with risk of autoantibody-positive rheumatoid arthritis at ten loci, seven of which represent new risk loci for rheumatoid arthritis. We estimate that the now >30 validated non-MHC rheumatoid arthritis risk alleles explain 3.9% of the total disease variance, with 0.67% of this variance being due to the new risk alleles reported here. It is clear that additional risk alleles remain to be identified, as current genetic discoveries explain only 16% of disease variance (including an estimated 12% for the MHC region 47 ), whereas more than half the risk of autoantibody-positive rheumatoid arthritis is thought to be genetic 47, 48 . The number of SNPs with suggestive evidence of association in our study ( Table 4 ) further indicates that many more common risk alleles with modest effect sizes remain to be discovered. In addition to common variants, the roles of rare variants, copy number variants and epigenetic modifications will need to be explored with newer genomic technologies. 
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